Seeking partners such as NGOs, academic institutions, and companies to expand and accelerate our portfolio of drugs for neglected diseases, including tropical infectious diseases.
Charles Bailey
Contact me for partnerships.
Partnering tabs - Therapy Areas " >Partnering tabs - Therapy Areas
Novartis is uniquely diversified across therapy areas with exposure to cutting-edge technology platforms. We have arguably the richest and broadest pipeline in the industry with more than 65 New Molecular Entities in development. Please select your therapy area of interest to connect to one of our specialist partnering professionals.
Seeking first in class and well differentiated, best in class treatments for moderate-severe Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Vitiligo, Alopecia Areata and severe forms of Acne as well as curative treatments for rare skin diseases.
Seeking transformative approaches to address genetic diseases.
Adam Simpson
Senior Director, Business Development (leads early-stage BD).
Elizabeth McMath
Associate Director, Global Search & Evaluation
Seeking new mechanisms of action and combination therapy partners for treating liver fibrosis and other non-viral liver diseases or promoting liver regeneration.
Interested in disease modifying therapies and disruptive approaches displacing existing standard of care in diseases including obesity and other areas with high unmet need.
Seeking to develop and deliver life-changing medicines for diseases and conditions from front to back of the eye, enabled by data, transformative technologies, and partnerships.
We are looking for partners to expand our portfolio with innovative and potentially transformative agents with a primary focus in subspeciality respiratory (e.g. IPF, sarcoidosis, bronchiectasis), COPD, food allergy, life threatening hospital conditions (e.g. ARDS, BPD) and Asthma.
Seeking projects with First in Class or Best in Class potential for moderate-severe Rheumatoid & Psoriatic Arthritis, Ankylosing Spondylitis, primary Sjoegren and Lupus with emphasis on oral treatments at par with biologics, or biologics with clear differentiation versus standard of care.
We accept that innovation happens outside of areas of interest- we are still prepared to discuss transformational areas we may have missed. We have a special team for you to talk with.
Oncology - Partnering tab " >Oncology - Partnering tab
Oncology
Exploring opportunities in areas where Novartis has active efforts, such as breast and lung cancers, melanoma, renal cell carcinoma, and malignant hematology; and we seek to expand into other high-unmet need areas such as hepatocellular, pancreatic, colorectal, and prostate cancers and others. Our partnering teams are organized by stage of development (clinical stage or early), tumour type, or biology of the intervention.
Hematology
Seeking partners to significantly improve standard of care and cure patients in selected high unmet need in benign hematology diseases. The vision is to transform a number of disease specific classes not limited to hemophilia, complement disorders, anemia, sickle cell disease and thalassemia.
Platform Collaborations - Partnering tab " >Platform Collaborations - Partnering tab
Seeking ways to transform patients’ lives by leading innovation in nuclear medicine and by investing in targeted Radioligand Therapy to treat advanced cancer – including advanced prostate cancer.
We are interested in partnerships that allow us to:
- Innovate around targets and vectors
- Identify or characterise new targets and receptor types specific to tumour cells or microenvironment.
- Innovate or access New Chelators, Linkers and Ligands, Develop New Therapeutic or Diagnostic Isotopes or Leverage our developed supply and distribution network.
David Benathan
Alberto Villena
Interested in biomarker and diagnostic technologies that are designed to optimize the efficiency, safety and therapeutic benefit of our drugs. Technologies may include genomic and proteomic testing as well as artificial intelligence driven solutions.
